Prognostic impact of pericardial effusion in patients with acute myocarditis
Authors:
- Matthieu ProustMPMatthieu Proust
- Florent HuangFHFlorent Huang
- Marie DupuyMDMarie Dupuy
- Estelle GandjbakhchEGEstelle Gandjbakhch
- Philippe CharronPCPhilippe Charron
- Alban RedheuilARAlban Redheuil
- Francesco RaveraFRFrancesco Ravera
- Benjamin BertinBBBenjamin Bertin
- Fleur Cohen-AubartFCFleur Cohen-Aubart
- Matthias PapoMPMatthias Papo
- 31 August 2026
- journal article
- Published by Oxford University Press (OUP) in European Heart Journal: Acute Cardiovascular Care
- Vol. 15 (10) , 741-751
Abstract
Aims: Recent Guidelines of the European Society of Cardiology have introduced the concept of Inflammatory Myocardial and Pericardial Syndrome (IMPS), a unified entity encompassing both myocarditis and pericarditis. This framework reflects the continuum between these conditions in term of anatomy, shared aetiologies, and a common diagnostic approach. This study sought (i) to describe factors associated with pericardial involvement; (ii) to compare the outcomes of patients hospitalized for proven acute myocarditis (AM) with or without pericardial effusion; (iii) to identify the independent correlates of clinical outcome. Methods and results: This is an observational ambispective cohort study based on the AMPHIBIA registry (Assistance Publique—Hôpitaux de Paris/ACTION Study Group), including patients hospitalized for proven AM between August 2008 and December 2024 at La Pitié Salpêtrière Hospital, Paris, France. Patients were stratified into two groups based on the presence of pericardial effusion on admission transthoracic echocardiography, ranging from minimal effusions to tamponade. The main composite outcome was defined as the occurrence of all-cause death, temporary mechanical circulatory support, severe ventricular arrhythmia, and heart transplantation, at the longest follow-up, up to 7 years. A total of 581 patients with AM were included [follow-up 3.7 (1.3–7.3) years]. Among them, 134 (23%) patients presented with pericardial effusion and 447 (77%) patients without. Four independent variables were associated with pericardial effusion at admission: left ventricular (LV) dysfunction, immunological myocarditis, elevated CRP, and fever. The occurrence of the composite event was significantly higher in patients with pericardial effusion compared to those without [38.1% vs. 15.7%, hazard ratio (HR) 2.69, 95% confidence interval (CI) (1.88–3.86), P < 0.001]. This difference was observed regardless of pericardial effusion size. After multivariable analysis, pericardial effusion was independently associated with the main composite outcome [HR 1.99 (1.32–3.00), P < 0.001. Conclusion: This study characterizes the phenotypes and outcomes of patients hospitalized for an AM, with and without pericardial effusion. Pericardial involvement was associated with LV dysfunction, immunological myocarditis, elevated CRP, and fever and was linked to a markedly higher risk of the composite outcome, remaining an independent predictor of adverse events. Differentiating these two phenotypes may provide physicians with valuable guidance for managing therapy in these patients.Keywords
Funding Information
- PHRA
- Fund for Folk Culture
This publication has 20 references indexed in Scilit:
- Clinical impact and prognostic significance of pericardial involvement in acute myocarditis: insights from a CMR studyThe International Journal of Cardiovascular Imaging, 2025
- Contemporary Epidemiology, Management, and In-Hospital Outcomes of Acute MyocarditisJACC: Heart Failure, 2025
- Rationale and design of the ARAMIS trial: Anakinra versus placebo, a double blind randomized controlled trial for the treatment of acute myocarditisArchives of Cardiovascular Diseases, 2023
- Phenotypic Heterogeneity of Fulminant COVID-19--Related Myocarditis in AdultsJACC, 2022
- Phase 3 Trial of Interleukin-1 Trap Rilonacept in Recurrent PericarditisNew England Journal of Medicine, 2021
- Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort studyThe Lancet Rheumatology, 2020
- Cardiovascular Magnetic Resonance in Nonischemic Myocardial InflammationJACC, 2018
- Inflammation and pericarditis: Are neutrophils actors behind the scenes?Journal of Cellular Physiology, 2018
- A Randomized Trial of Colchicine for Acute PericarditisNew England Journal of Medicine, 2013
- Myocarditis: The Dallas criteriaHuman Pathology, 1987